Flat revenue masked by one-off gain; Q2 monsoon upside ahead

₹386 Cr vs ₹377 Cr Q1 FY26 (+2.4% YoY); down 4.1% QoQ from ₹402.5 Cr prior quarter

16% growth is QoQ (vs ₹22.76 Cr in Q4), not YoY; stripped of ₹5.7 Cr land sale one-off, operational PAT flat YoY

Domestic stable, export weak (10% of revenue), temporary RM constraints cited

Gaining scales/volumes in B2C, but still only 20-22% of B2C segment (hence ~10% of total revenue)

Launched PCT 410, Fighter gaining scales/volumes in Q1 with strong B2B co-marketing uptake. Aim to double patented share in 3 years (from 20-22% to 40-50% of B2C).

Brazil demand softer (geopolitical volatility, customer holdback, China logistics advantage), temporary RM constraints. 10% of revenue vs prior guidance aspiration for growth.

Employee costs up (annual increments), power/fuel up (coal rates), raw material volatility from geopolitics and 10-11% rupee depreciation. Time lag to pass through in B2C.

Technical utilization 70-75% (scope to grow), formulation 25-30% (designed for peak season). Multi-product plants allow high-value low-volume swaps for new patented launches.

Q1 hit by El Nino/geopolitical caution; July 2026 monsoon now supportive, acreage green across cotton/soybean/chillies. Management expects strong Q2 momentum.

Current: B2C branded 45%, B2B 45%, export 10%. Formulation 75%, technical 25%. Patented products 20-22% of B2C; aiming to double in 3 years.

Loan repayment complete. Small amount pending brokerage settlement (2-3 months). IPO account closure imminent.

Volatility from geopolitics and rupee depreciation (-10-11%) offset by product mix shift. Inventory covers cost lag in B2C; B2B passes through to customers.

Brazil cautious (liquidity issues, credit challenges, China logistics advantage). Focusing on established B2B customers. Expanding to Argentina/Uruguay with second-tier distributors.

Q1 hit by El Nino caution. July monsoon now good, acreage up (cotton, soybean, chillies, paddy stable). Insect pressure will benefit GSP's insecticide/fungicide strength. Q2 expected strong.

Introduced 12 products in 3 years; no saturation expected next 3-4 years. Target: double patented share in 2-3 years. Expanding to herbicides and potato (gap segments).

Technical 70-75% (scope to grow); multi-product plants allow high-value/low-volume swaps. Formulation 25-30% (designed for peak season, not bottleneck).

Yes, formulation focus. B2C branded main goal, supported by B2B (filling portfolio gaps with patented formulations). Market share 3-3.5%, targeting 7-8%.

Farmers increasingly aware (West Bengal example), adopting specialty chemicals, moving toward preventive spraying (like developed markets). New generation more digitally connected.

Technical R&D: 1-2 new products/year for next 5 years (4-5 year data generation cycle). Formulation R&D: 2-3 patented formulations/year for next 4-5 years. Pipeline robust.

Primary focus: Latin America (Brazil, USA), reverse season to India allows 12-month plant utilization. Secondary: Africa, Asia. Volume/value focus on LatAm.

Three differentiators: (1) newer technical molecules getting off-patent, (2) holistic farmer solutions via field trials, (3) innovative formulations (SE, ZC, OD). First-mover advantage on off-patent technicals.

Revenue: ~15% growth; EBITDA: 13-14% margin in next 2-3 years. Milestones: patented mix doubling, market share 7-8%, new product launches, capacity utilization.

PAT segmentation difficult due to common costs. Margin expansion from patented products in B2C and good B2B margins. PAT upside also from reduced interest cost.

₹5.7 Cr from land sale to promoter (66,000 sqm for ₹23 Cr approved). No other land sales planned. One-off; expect lower other income run rate going forward.

Material supply now clear (not constraint). Monsoon July supportive covering major part. On track to achieve anticipated growth. South India (AP/Tel/KA) under watch on monsoon.

Domestic 80%, export 20%. B2B and B2C currently ~40% each. 3-year target: B2C 45-50%, B2B 30-35%, export ~20%.

Driven by patented product mix shift (targeting 40-50% of B2C in 3 years) and market share expansion (3-3.5% to 7-8%).

Uplift from mix shift to patented products (higher margin) and interest cost reduction post-IPO debt repayment.

Brazil (largest export market) facing demand caution, liquidity/credit constraints, and China logistics advantage. Temporary supply constraints in H1 causing delays and order losses.

Geopolitical volatility (petrochemical linkage), 10-11% rupee depreciation, and coal rate increases pushing RM prices higher. Time lag to pass through to B2C customers; B2B can pass through.

Annual wage increments and slight headcount increase in Q1 pressuring margins. Partially offset by gross margin expansion but reduces bottom-line upside.

Core strategy hinges on delivering 1-2 new technical molecules/year and 2-3 new patented formulations/year for 4-5 years. Regulatory delays, field trial failures, or farmer adoption shortfalls could derail mix expansion from 20-22% to 40-50% in 3 years.

Business is Kharif-led (Q2 represents ~60% of annual PAT). Poor monsoon, pest cycles, or farmer sentiment shifts could materially impact annual performance.

₹5.7 Cr land sale to promoter-group Indo-GSP represents 22% of reported Q1 PAT. Operational earnings flat YoY; headline growth misleading without disclosure.

Company relies on imports for some technical molecules; backward integration underway but not yet complete. Geopolitical supply shocks could disrupt sourcing.